The effect of GnRH analog treatment on BMI in children treated for precocious puberty: a systematic review and meta-analysis

Zhu, Xiaoxiao; Qin, Jiajia; Xue, Weirong; Li, Shengli; Zhao, Meng; Yingliang Jin,

doi:10.1515/jpem-2023-0416

Cited by 2 publications

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

A Phase 3, Open-Label, Single-Arm Trial of the Efficacy and Safety of Triptorelin 6-Month Formulation in Chinese Children with Central Precocious Puberty

Yu,

Cheng,

Wei

et al. 2024

Adv Ther

View full text Add to dashboard Cite

Introduction This phase 3 study assessed the efficacy, safety, and pharmacokinetics of the 6-month prolonged release (PR) formulation in Chinese children with central precocious puberty (CPP). Methods In this open-label study (NCT05029622), Chinese children (girls < 9 years, boys < 10 years) received two doses of triptorelin pamoate 22.5 mg (day 1 and month 6). Primary endpoint was the proportion at month 6 with luteinizing hormone (LH) suppression (stimulated peak LH ≤ 5 IU/L after gonadotropin-releasing hormone stimulation). Secondary endpoints included safety assessments, hormone level changes, and clinical parameters from baseline. Results Overall, 66 children completed the study (93.9% girls; median age 8.0 [range 5–9] years). At month 6, all patients had LH suppression; this was maintained at month 12 in 98.5% of patients. Mean basal and peak LH and follicle-stimulating hormone levels were suppressed throughout follow-up. All patients at months 3 to 12 had sex hormone suppression to prepubertal levels. Stable or reduced breast development was seen for 98.4% and 93.5% of girls at month 6 and 12, respectively; all boys had regression or stable genital development until month 12. Compared with baseline (9.82 cm/year), mean growth velocity was 5.88 cm/year at month 6 and 5.17 cm/year at month 12. Mean bone age/chronological age ratio decreased from 1.27 at baseline to 1.23 and 1.21 at month 6 and 12, respectively. In girls, 64.5% showed decreased uterine length at month 6 and 12 versus baseline, while 75.0% of boys showed stable testicular volume versus baseline. Thirteen patients (19.7%) had 22 drug-related treatment emergent adverse events (TEAEs); no grade ≥ 3 TEAEs were reported. Conclusion The efficacy and safety profile of triptorelin 6-month PR in Chinese children with CPP was consistent with data previously reported in non-Chinese children with CPP, supporting this as a viable treatment option for Chinese children with CPP. Trial Registration Trial registration: ClinicalTrials.gov identifier, NCT05029622.

show abstract

A Phase 3, Open-Label, Single-Arm Trial of the Efficacy and Safety of Triptorelin 6-Month Formulation in Chinese Children with Central Precocious Puberty

Yu,

Cheng,

Wei

et al. 2024

Adv Ther

View full text Add to dashboard Cite

show abstract

Gonadotropin-Releasing Hormone Analogue Treatment: Differentiating Effects on Body Mass Index in Normal-Weight, Overweight, and Obese Girls

Thaneetrakool,

Aroonparkmongkol,

Numsriskulrat

et al. 2024

Preprint

View full text Add to dashboard Cite

Introduction: Weight gain and BMI changes are concerns while treating central precocious puberty (CPP) with gonadotropin-releasing hormone agonist (GnRHa). This study investigates BMI changes with GnRHa treatment in idiopathic CPP girls of normal, overweight, and obese weight. Method: This study collected data from 188 girls with idiopathic CPP who received GnRHa therapy. BMI changes were analyzed during the treatment period, with participants stratified based on their baseline BMI status: normal weight (BMI < 1 SDS), overweight (BMI ≥ 1 SDS), and obese (BMI ≥ 2 SDS). Results: Obesity and overweight were prevalent, observed in 24.5% and 14.9% of the cases, respectively. The BMI-SDS of the normal-weight group increased significantly during the treatment period at the beginning of treatment, 12-months after treatment, and the end of treatment (0.01 ± 0.7, 0.23 ± 0.9, and 0.37 ± 1.0, P < 0.05). However, no significant changes in BMI-SDS were noted in the overweight and obese groups during the treatment period. Conclusion: The findings of our study indicate that the variations in BMI alterations observed in our CPP patients imply that the impact of GnRHa treatment-induced delayed puberty on linear growth may differ based on the initial body composition.

show abstract

The effect of GnRH analog treatment on BMI in children treated for precocious puberty: a systematic review and meta-analysis

Cited by 2 publications

References 49 publications

A Phase 3, Open-Label, Single-Arm Trial of the Efficacy and Safety of Triptorelin 6-Month Formulation in Chinese Children with Central Precocious Puberty

A Phase 3, Open-Label, Single-Arm Trial of the Efficacy and Safety of Triptorelin 6-Month Formulation in Chinese Children with Central Precocious Puberty

Gonadotropin-Releasing Hormone Analogue Treatment: Differentiating Effects on Body Mass Index in Normal-Weight, Overweight, and Obese Girls

Contact Info

Product

Resources

About